Navigation Links
Isis Scientist Awarded 2009 Ebert Prize

CARLSBAD, Calif., April 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Lloyd G. Tillman, Ph.D., Executive Director of Pharmaceutical Development of Isis has been awarded the American Pharmacists Association's (APhA) 2009 Ebert Prize. Dr. Tillman received the award at the APhA Annual Meeting and Exposition, April 3-6, 2009, in San Antonio, TX, for work published in the Journal of Pharmaceutical Sciences entitled "Oral Delivery of Antisense Oligonucleotides in Man." His co-authors are Richard S. Geary, Ph.D. and Gregory E. Hardee, Ph.D. (1)

"I am deeply honored to be acknowledged by the APhA and presented with this year's Ebert award. I would like to recognize my co-authors, whose advice and hard work contributed significantly to this publication," said Lloyd Tillman. "Our work demonstrated, for the first time, that antisense drugs could be administered orally. The feasibility of oral administration has dramatically broadened the therapeutic and commercial potential of antisense drugs."

The research, which was published in January 2008, provided proof-of-concept for the oral administration of antisense drugs in a single-dose study in man. Scientists at Isis continue to research advances to enhance the pharmaceutical properties of antisense drugs, including oral bioavailability.

"We are pleased that Dr. Tillman was recognized by the APhA to receive this award on our seminal work in advancing the oral delivery of antisense drugs. Creating antisense drugs that can be administered orally continues to be an area of active research for Isis, as oral administration can offer patients and physicians increased convenience and enhance the commercial profile of our antisense drugs," said Richard S. Geary, Ph.D., Isis' Senior Vice President, Development. "Since this research, we have completed a multiple-dose Phase 1 study that provided further evidence that antisense drugs are active and well-tolerated when administered orally."

The Ebert Prize was established in 1873 by the APhA and is the oldest pharmacy award in the United States awarded annually to researchers who have reported significant results for original investigation published in the Journal of Pharmaceutical Sciences.

(1) Lloyd Tillman, Richard S. Geary, Gregory E. Hardee. Oral Delivery of Antisense Oligonucleotides in Man. Journal of Pharmaceutical Sciences. 2008; 97 (1): 225-36.


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at

This press release includes forward-looking statements regarding Isis' discovery and development of antisense drugs and the potential for Isis' development of antisense drugs that can be administered orally. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2008, which is on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 10, ... States District Court of Connecticut on behalf of a home health care worker who ... current or former home health care workers employed by Humana, Inc., Humana at Home, ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Today, ... on our nation’s roadways has dropped below 10,000 for the first time since 2011. ... in 2013. , According to data released by the National Highway Traffic Safety Administration ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... of philanthropic seniors, is resulting in a way for homeless people to have ... Schaumburg have launched a new initiative whereby they are repurposing plastic bags into ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , November 25, 2015 ... due to repeated failure of IVF cycles. After failure ... was totally dejected and had lost all hopes that she would be able ... Indian miracle child conceived after failure of over 15 ... abroad (UK) before they decided to take one last attempt with ...
(Date:11/24/2015)... SAN CARLOS, Calif. , Nov. 24, ... ), a leader in non-invasive genetic testing ... today announced that it will present at ... Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ... discuss the Company,s financial results, business activities ...
(Date:11/24/2015)... /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") ... the first patient has been enrolled in ESSA,s Phase ... metastatic castration-resistant prostate cancer ("mCRPC"). the ... the United States and Canada.  ... trial, ESSA intends to demonstrate the safety, tolerability, maximum ...
Breaking Medicine Technology: